LCS
PRME icon

Levin Capital Strategies’s Prime Medicine PRME Stock Holding History

Levin Capital Strategies’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,000
Closed -$155K – 264
2024
Q3 		$155K Buy
+40,000
New +$185K 0.01% 199

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Levin Capital Strategies's PRME Position: Q1 2026 in Review

Levin Capital Strategies held its Prime Medicine (PRME) position steady in Q1 2026 at 15,000 shares worth $52.2K. The position accounts for ﹤0.01% of the portfolio, ranked #230.

Levin Capital Strategies first reported a position in PRME in Q4 2022 and has held it in 11 quarters since. The position peaked at $346K in Q2 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Levin Capital Strategies held 15,000 shares of Prime Medicine worth $52.2K as of Q1 2026.
  • Levin Capital Strategies left its Prime Medicine share count unchanged in Q1 2026.
  • Prime Medicine made up ﹤0.01% of Levin Capital Strategies's portfolio in Q1 2026, its #230 holding.
  • Levin Capital Strategies first reported a position in Prime Medicine in Q4 2022 and has held it in 11 quarters since.
  • Levin Capital Strategies's Prime Medicine position peaked at $346K in Q2 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Levin Capital Strategies's 13F filing for Q1 2026, filed 13 May 2026.